Abstract:Leucine-rich repeat kinase 2 ( LRRK2 ) is the most common gene responsible for familial Parkinson's disease (PD). The gene product of LRRK2 contains multiple protein domains, including armadillo repeat, ankyrin repeat, leucine-rich repeat (LRR), Ras-of-complex (ROC), C-terminal of ROC (COR), kinase, and WD40 domains. In this study, we performed genetic screening of LRRK2 in our PD cohort, detecting sixteen LRRK2 rare variants. Among them, we selected seven variants that are likely to be familial and characterized them in terms of LRRK2 protein function, along with clinical information and one pathological analysis. The seven variants were S1120P and N1221K in the LRR domain; I1339M, S1403R, and V1447M in the ROC domain; and I1658F and D1873H in the COR domain. The kinase activity of the LRRK2 variants N1221K, S1403R, V1447M, and I1658F toward Rab10, a well-known phosphorylation substrate, was higher than that of wild-type LRRK2. LRRK2 D1873H showed enhanced self-association activity, whereas LRRK2 S1403R and D1873H showed reduced microtubule-binding activity. Pathological analysis of a patient with the LRRK2 V1447M variant was also performed, which revealed Lewy pathology in the brainstem. No functional alterations in terms of kinase activity, self-association activity, and microtubule-binding activity were detected in LRRK2 S1120P and I1339M variants. However, the patient with PD carrying LRRK2 S1120P variant also had a heterozygous Glucosylceramidase beta 1 ( GBA1 ) L444P variant. In conclusion, we characterized seven LRRK2 variants potentially associated with PD. Five of the seven variants in different LRRK2 domains exhibited altered properties in kinase activity, self-association, and microtubule-binding activity, suggesting that each domain variant may contribute to disease progression in different ways.

The emerging role of LRRK2 in tauopathies

Clinical and Functional Evidence for the Pathogenicity of the LRRK2 P.arg1067gln Variant

The Role of the LRRK2 Gene in Parkinsonism

Is Glial Dysfunction the Key Pathogenesis of LRRK2-Linked Parkinson's Disease?

Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson's Disease

LRRK2, a puzzling protein: Insights into Parkinson's disease pathogenesis

Advance of the Study on LRRK2 Gene in Parkinson's Disease

How Parkinson's Disease-Linked LRRK2 Mutations Affect Different CNS Cell Types

LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression

Clinical characteristics and pathophysiological properties of newly discovered LRRK2 variants associated with Parkinson's disease

LRRK2 Kinase Activity Does Not Alter Cell-Autonomous Tau Pathology Development in Primary Neurons

Leucine-Rich Repeat Kinase 2 Regulates the Progression of Neuropathology Induced by Parkinson's-Disease-Related Mutant Α-Synuclein

Mouse models for LRRK2 Parkinson's disease.

Clinical Features and Mutation Analysis of LRRK2 Gene in Patients with Autosomal Dominant Familial Parkinson's Disease

Cell-autonomous role of leucine-rich repeat kinase in the protection of dopaminergic neuron survival

Proteome wide association studies of LRRK2 variants identify novel causal and druggable proteins for Parkinson's disease

The LRRK2 kinase substrates RAB8a and RAB10 contribute complementary but distinct disease-relevant phenotypes in human neurons

Genetic Insights into Sporadic Parkinson's Disease Pathogenesis

Leucine-Rich Repeat Kinases

LRRK2 to the rescue of damaged endomembranes

Misfolded protein propagation in an integrated computational model of structural network and <i>LRRK2</i> gene expression